Human tumor cells killed by anthracyclines induce a tumor-specific immune response

Cancer Research

Volumn 71, Issue 14, 2011, Pages 4821-4833

  Fucikova, Jitka ^a   Kralikova, Petra ^a   Fialova, Anna ^a   Brtnicky, Tomas ^b   Rob, Lukas ^b   Bartunkova, Jirina ^a   Špíšek, Radek ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CALRETICULIN; CD83 ANTIGEN; CD86 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GAMMA INTERFERON; GEMCITABINE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HIGH MOBILITY GROUP B1 PROTEIN; HLA DR ANTIGEN; IDARUBICIN; IFOSFAMIDE; LEUPRORELIN; TOLL LIKE RECEPTOR 4;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN PRESENTATION; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CD4+ CD25+ T LYMPHOCYTE; CELL DEATH; CELL MATURATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; OVARY CANCER; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN SECRETION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TUMOR CELL; ULTRAVIOLET RADIATION;

ANTHRACYCLINES; CALRETICULIN; CELL DEATH; CELL LINE, TUMOR; DENDRITIC CELLS; FEMALE; HMGB1 PROTEIN; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MALE; NEOPLASMS; OVARIAN NEOPLASMS; PHAGOCYTOSIS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROSTATIC NEOPLASMS; T-LYMPHOCYTES;

EID: 79960406242     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-0950     Document Type: Article

References (30)

1. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006;6:715-27. (Pubitemid 44453458)
2. Green JE, Hudson T. The promise of genetically engineered mice for cancer prevention studies. Nat Rev Cancer 2005;5:184-98. (Pubitemid 40314950)
3. Galluzzi L, Maiuri MC, Vitale I, Zischka H, Castedo M, Zitvogel L, et al. Cell death modalities: classification and pathophysiological implications. Cell Death Differ 2007;14:1237-43. (Pubitemid 46969863)
4. Spisek R, Dhodapkar MV. Towards a better way to die with chemotherapy: role of heat shock protein exposure on dying tumor cells. Cell Cycle 2007;6:1962-5. (Pubitemid 47327881)
5. Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar M. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 2007;109:4839-45. (Pubitemid 46827780)
6. Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 2008;15:3-12. (Pubitemid 350286167)
7. Panaretakis T, Joza N, Modjtahedi N, Tesniere A, Vitale I, Durchschlag M, et al. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ 2008;15:1499-509.
8. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13:1050-9. (Pubitemid 47517504)
9. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007;13:54-61. (Pubitemid 46067386)
10. Obeid M, Panaretakis T, Joza N, Tufi R, Tesniere A, van Endert P, et al. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 2007;14:1848-50. (Pubitemid 47423653)
11. Martins I, Kepp O, Galluzzi L, Senovilla L, Schlemmer F, Adjemian S, et al. Surface-exposed calreticulin in the interaction between dying cells and phagocytes. Ann N Y Acad Sci 2010;1209:77-82.
12. Apetoh L, Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Piacentini M, et al. Immunogenic chemotherapy: discovery of a critical protein through proteomic analyses of tumor cells. Cancer Genomics Proteomics 2007;4:65-70. (Pubitemid 46632027)
13. Demaria S, Santori FR, Ng B, Liebes L, Formenti SC, Vukmanovic S. Select forms of tumor cell apoptosis induce dendritic cell maturation. J Leukoc Biol 2005;77:361-8. (Pubitemid 40289566)
14. Sochorova K, Budinsky V, Rozkova D, Tobiasova Z, Dusilova-Sulkova S, Spisek R, et al. Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells. Clin Immunol 2009;133:69-77.
15. Rozkova D, Horvath R, Bartunkova J, Spisek R. Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite upregulation of Toll-like receptors. Clin Immunol 2006;120:260-71. (Pubitemid 44175897)
16. Boura E, Liebl D, Spisek R, Fric J, Marek M, Stokrova J, et al. Polyomavirus EGFP-pseudocapsids: analysis of model particles for introduction of proteins and peptides into mammalian cells. FEBS Lett 2005;579:6549-58. (Pubitemid 41682438)
17. Spisek R, Chevallier P, Morineau N, Milpied N, Avet-Loiseau H, Harousseau JL, et al. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin. Cancer Res 2002;62:2861-8. (Pubitemid 34525772)
18. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005;202:1691-701. (Pubitemid 41815875)
19. Zitvogel L, Casares N, Pequignot MO, Chaput N, Albert ML, Kroemer G. Immune response against dying tumor cells. Adv Immunol 2004;84:131-79. (Pubitemid 38887680)
20. Masse D, Ebstein F, Bougras G, Harb J, Meflah K, Gregoire M. Increased expression of inducible HSP70 in apoptotic cells is correlated with their efficacy for antitumor vaccine therapy. Int J Cancer 2004;111:575-83. (Pubitemid 39045325)
21. Shi H, Cao T, Connolly JE, Monnet L, Bennett L, Chapel S, et al. Hyperthermia enhances CTL cross-priming. J Immunol 2006;176:2134-41. (Pubitemid 43201660)
22. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002;418:191-5. (Pubitemid 34773774)
23. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-51. (Pubitemid 29329996)
24. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D, Sohn JW, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006;290:C917-24.
25. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004;279:7370-7. (Pubitemid 38294612)
26. Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalanotti F, Giazzon M, et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 2004;5:825-30. (Pubitemid 39199174)
27. Banerjee DK, Dhodapkar MV, Matayeva E, Steinman RM, Dhodapkar KM. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 2006;108:2655-61.
28. Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 2002;195:125-33. (Pubitemid 34074502)
29. Spisek R. Immunoprevention of cancer: time to reconsider timing of vaccination against cancer. Expert Rev Anticancer Ther 2006;6:1689-91. (Pubitemid 46062303)
30. Spisek R, Dhodapkar MV. Immunoprevention of cancer. Hematol Oncol Clin North Am 2006;20:735-50. (Pubitemid 43817438)